Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
This article was originally published in PharmAsia News
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.
You may also be interested in...
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area
AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio